Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 39 | 2,540 | 22% |
| 2020 | 36 | 2,297 | 25% |
| 2021 | 37 |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 68% of the cases CMS names in Mississippi; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 37 | 1,533+9.3%/yr | +9.3%/yr | 3.61.0× | 28% | 2,480 in 2030+8.3%/yr |
| EP ablation |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Florida
| 2024 |
| 1,618 |
| 46% |
| 2025 est. | ≈ 1,550 | – |
| 2026 est. | ≈ 1,540 | – |
| 2,214 |
| 32% |
| 2022 | 35 | 1,985 | 37% |
| 2023 | 36 | 1,939 | 42% |
| 2024 | 27 | 1,618 | 46% |
| 2025 from claims | – | 1,545 1,418–1,635 | 47% |
| 2026 forecast | – | 1,538 1,353–1,775 | 48% |
| 2027 forecast | – | 1,529 1,307–1,822 | 49% |
| 2028 forecast | – | 1,519 1,267–1,860 | 50% |
| 2029 forecast | – | 1,508 1,232–1,892 | 51% |
| 2030 forecast | – | 1,497 1,200–1,919 | 52% |
In 2025, 35% inpatient hospital, 59% hospital outpatient, 6% surgery center. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~1,500 | ~540 | ~900 | ~93 |
| 2027 · ~1,500 | ~540 | ~890 | ~95 |
| 2028 · ~1,500 | ~540 | ~880 | ~95 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 58% (59% in 2025).
| −3.2%/yr |
| 5.8 |
| 7% |
| 12,500 in 2030+0.7%/yr |
| Virginia | 89 | 5,169−2.2%/yr | −2.2%/yr | 5.1 | 6% | 5,360 in 2030+0.6%/yr |
| North Carolina | 100 | 4,907−3.4%/yr | −3.4%/yr | 5.2 | 0% | 5,080 in 2030+0.6%/yr |
| Tennessee | 79 | 4,585−3.7%/yr | −3.7%/yr | 6.8 | 1% | 4,450 in 2030−0.5%/yr |
| Georgia | 88 | 4,562−3.7%/yr | −3.7%/yr | 5.5 | 0% | 5,000 in 2030+1.5%/yr |
| South Carolina | 68 | 3,818−0.9%/yr | −0.9%/yr | 5.8 | 1% | 4,480 in 2030+2.7%/yr |
| Maryland | 50 | 3,380−1.5%/yr | −1.5%/yr | 3.9 | 1% | 3,330 in 2030−0.2%/yr |
| Arkansas | 40 | 2,434−5.8%/yr | −5.8%/yr | 6.7 | 0% | 2,160 in 2030−1.9%/yr |
| Alabama | 51 | 2,358−6.8%/yr | −6.8%/yr | 5.6 | 0% | 2,180 in 2030−1.3%/yr |
| Oklahoma | 41 | 2,342−5.8%/yr | −5.8%/yr | 5.0 | 3% | 2,290 in 2030−0.4%/yr |
| Louisiana | 38 | 2,141−6.6%/yr | −6.6%/yr | 5.5 | 9% | 1,980 in 2030−1.3%/yr |
| Kentucky | 43 | 2,124−7.2%/yr | −7.2%/yr | 4.8 | 0% | 1,980 in 2030−1.2%/yr |
| West Virginia | 18 | 1,108−1.5%/yr | −1.5%/yr | 5.5 | 0% | 1,020 in 2030−1.4%/yr |
| Delaware | 13 | 724−4.8%/yr | −4.8%/yr | 4.3 | 0% | 790 in 2030+1.4%/yr |
| District of Columbia | 10 | 494−2.1%/yr | −2.1%/yr | 8.1 | 0% | 510 in 2030+0.4%/yr |
| 10 |
| 693−0.9%/yr |
| −0.9%/yr |
| 1.60.4× |
| 0% |
| 1,160 in 2030+9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Cvrx leads with 43% of company spending on these surgeons in 2025, +33 pts on 2024.
In 2025, 9 companies reported engagement with Mississippi’s surgeons worth $85K in consulting, speaking, meals and travel tied to these products, about $3,164 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.